Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing targeted therapies for oncology and related immunologic diseases. The company's commercial portfolio features two primary therapies: Revuforj (revumenib), a selective menin inhibitor approved for genetically defined acute leukemias, and Niktimvo (axatilimab), a monoclonal antibody targeting the CSF-1 receptor for the treatment of chronic graft-versus-host disease. Beyond its approved indications, Syndax is advancing a clinical pipeline that explores these assets in earlier lines of therapy and in combination with standard-of-care treatments. The company's research and development strategy emphasizes precision medicine, utilizing genetic analysis and immunomodulation to overcome drug resistance in both hematologic malignancies and solid tumors. Syndax collaborates with academic institutions and other pharmaceutical companies to accelerate the clinical development of its proprietary drug candidates.
